Analysts Set Genocea Biosciences, Inc. (NASDAQ:GNCA) Price Target at $18.78

Genocea Biosciences, Inc. (NASDAQ:GNCA) has been given a consensus recommendation of “Buy” by the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $18.78.

A number of equities research analysts have commented on GNCA shares. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Tuesday, May 16th. ValuEngine cut shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Monday, July 24th. Cowen and Company restated an “outperform” rating and set a $40.00 target price on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $18.00 target price (up previously from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th.

In other Genocea Biosciences news, CFO Jonathan Poole sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the sale, the chief financial officer now owns 84,247 shares in the company, valued at approximately $505,482. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.70% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after buying an additional 18,574 shares during the period. Northpointe Capital LLC raised its stake in shares of Genocea Biosciences by 9.6% in the second quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock worth $6,974,000 after buying an additional 117,374 shares during the period. Geode Capital Management LLC raised its stake in shares of Genocea Biosciences by 4.7% in the first quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock worth $903,000 after buying an additional 6,708 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Genocea Biosciences by 594.6% in the second quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock worth $439,000 after buying an additional 72,008 shares during the period. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Genocea Biosciences during the second quarter worth about $257,000. 54.24% of the stock is owned by institutional investors and hedge funds.

Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 3.80% during trading on Friday, reaching $4.81. 419,977 shares of the company traded hands. The company’s 50-day moving average price is $5.30 and its 200-day moving average price is $5.50. Genocea Biosciences has a 52 week low of $3.28 and a 52 week high of $7.29. The company’s market capitalization is $137.09 million.

TRADEMARK VIOLATION NOTICE: This piece of content was published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/analysts-set-genocea-biosciences-inc-nasdaqgnca-price-target-at-18-78-updated.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply